Clinical trial
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With…
NCT03823300 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT03823300 |
|---|---|
| Title | A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE) |
| Official title | A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Neovascular Age-Related Macular Degeneration (LUCERNE) |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Wet Macular Degeneration |
| Intervention type | Drug, Procedure |
| Interventions | Faricimab, Aflibercept, Sham Procedure |
| Enrollment | 658 |
| Start date | Mar 11, 2019 |
| Primary completion | Oct 5, 2020 |
| Completion | Jan 7, 2022 |
| First posted | Jan 30, 2019 |
| Last update posted | Jul 11, 2025 |
| Countries | Argentina, Australia, Austria, Brazil, Bulgaria, China, Denmark, France, Germany, Hong Kong, Hungary, Italy and 9 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: